| September 4, 2014 | ISSUE NUMBER 367 VOL 4 |
|
Pricing
Pharma Battles Hospitals Over Discount Pricing Program
Continued growth in a federal program that provides low-cost drugs to safety-net hospitals — established in 1992 under section 340B of the Public Health Service Act — has sparked “trench warfare” over which medicines and providers are eligible for the deep discounts, and whether program expansion has undermined the original intent of the law, writes Jill Wechsler ...Read more
Training
Executive Coaching: Transforming Big Pharma from Within
Rick Koonce outlines the critical coaching steps to help top managers realize their potential in an industry undergoing significant restructuring of both human and financial capital ...Read more
Inspection Focus in Clinical Trials Using a Risk-Based Monitoring Approach
How will clinical trials that adopt an RBM approach be inspected? Covance shares actionable insights to start answering this vitally important question.  Learn More
Europe
More Direct-Acting Antivirals, More Controversy
The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza. Peter O’ Donnell reports
...Read more
Global
Read the New Pharm Exec Global Digest: Technology Special
In the latest issue, featuring UBISTART, the US-French payout initiative for new startups; Fixing the Medical Technology Disconnect; the Future of Safety Signal Detection and Risk Management; Wearable Healthcare Technology; and more
...Read more
Sunshine is Over. Now What?!
You’ve compiled all your HCP spend data and submitted your Sunshine reports. What’s next? Use your transparency data to your advantage. With an innovative new dashboard, you can leverage advanced analytics to gain more insight into your HCP programs than ever before. Learn how you can streamline business and compliance processes and.  improve the efficiency of your HCP programs.
Emerging Pharma Leaders
Pharm Exec’s Emerging Pharma Leaders 2014
This year's class of 15 young executives is deeply of the moment, with assignments that include advancing therapies against hepatitis C, building new cell-based platforms in regenerative medicine, creating new businesses beyond a protected home base, and transforming raw data into "news I can use" analytics
...Read more
Engineer Your Business to Win in the Mobile Selling Moment
Live Webinar: Thursday, September 25, 2014 12pm ET
Smartphones and tablets are becoming an extension of our brains. When we don’t immediately find what we want, we turn to our phone or tablet and look for a service to help. This is just as true for healthcare providers (HCPs) and employees as for consumers. In this webcast, you’ll learn to identify the mobile moments critical to engaging HCPs.
Register Free at  www.pharmexec.com/mobileselling
|
|
|
|
 //Mary Kay Deck joined Intelomed (Pittsburgh, PA) as Vice President of Clinical Affairs.//Celator Pharmaceuticals (Ewing, NJ) named Michael R. Dougherty Chairman of the Board of Directors.//Cerenis Therapeutics (Ann Arbor, MI and Toulouse, France) appointed Richard C. Pasternak, MD, as Chairman of the Board of Directors. He will take over from Dr. Jean-Pierre Garnier, who is stepping down for personal reasons..//Nabriva Therapeutics AG (Vienna, Austria) named Dr Colin Broom as Chief Executive Officer. Current CEO Ralf Schmid will move to the role of COO and CFO. The company also announced the establishment of a US subsidiary, based in Philadelphia, PA, where the clinical development team will be located.//
|
|
|
|
|
|
 |
|
 |
|
| |
|
 |
What is your key area of concern regarding your company’s future?
|
|
|
|
